Cargando…

Outcomes of 596 Advanced Gastric Cancer Patients with Different Numbers of Chemotherapy Lines: The More Chemotherapy Lines, the Better Survival

OBJECTIVE: Many large-sample prospective randomized clinical trials investigating advanced gastric cancer (AGC) have confirmed the survival advantages of first-line, second-line, or third-line chemotherapy compared with their respective control groups. However, due to the ethical concerns of prospec...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sun, Li, Wang, Huijun, Liu, Zhen, Meng, Ying, Qiu, Meiqing, Ju, Yafei, Zhang, Shu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7602914/ https://www.ncbi.nlm.nih.gov/pubmed/33149671 http://dx.doi.org/10.2147/CMAR.S275990

Ejemplares similares

Progression-free survival as a surrogate endpoint for overall survival in patients with third-line or later-line chemotherapy for advanced gastric cancer
por: Liu, Liya, et al.
Publicado: (2015)

S-1-Based Chemotherapy versus Capecitabine-Based Chemotherapy as First-Line Treatment for Advanced Gastric Carcinoma: A Meta-Analysis
por: He, Ming-ming, et al.
Publicado: (2013)

MicroRNA-596 acts as a tumor suppressor in gastric cancer and is upregulated by promotor demethylation
por: Zhang, Zhen, et al.
Publicado: (2019)

Correction to “MicroRNA-596 acts as a tumor suppressor in gastric cancer and is upregulated by promotor demethylation”
por: Zhang, Zhen, et al.
Publicado: (2022)

Metronomic chemotherapy: changing the paradigm that more is better
por: Scharovsky, O.G., et al.
Publicado: (2009)

Survival Outcomes Following Combination of First-Line Platinum-Based Chemotherapy with S-1 in Patients with Advanced Gastric Cancer
por: Koumarianou, Anna, et al.
Publicado: (2020)

Second-line chemotherapy for patients with advanced gastric cancer: who may benefit?
por: Catalano, V, et al.
Publicado: (2008)

A retrospective analysis of second-line chemotherapy in patients with advanced gastric cancer
por: Ji, Sang Hoon, et al.
Publicado: (2009)

Paclitaxel combined with capecitabine as first-line chemotherapy for advanced or recurrent gastric cancer
por: YUAN, MEIQIN, et al.
Publicado: (2014)

Third-line docetaxel chemotherapy for recurrent and metastatic gastric cancer
por: Lee, Ji Hyun, et al.
Publicado: (2013)

First Line and Second Line Chemotherapy in Advanced Cholangiocarcinoma and Impact of Dose Reduction of Chemotherapy: A Retrospective Analysis
por: Möhring, Christian, et al.
Publicado: (2021)

Cost-Effectiveness of Nivolumab Plus Chemotherapy vs. Chemotherapy as First-Line Treatment for Advanced Gastric Cancer/Gastroesophageal Junction Cancer/Esophagel Adenocarcinoma in China
por: Shu, Yamin, et al.
Publicado: (2022)

Nivolumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: a cost-effectiveness analysis
por: Zhang, Peng-Fei, et al.
Publicado: (2023)

Outcomes of Advanced Gastric Cancer Patients Treated with at Least Three Lines of Systemic Chemotherapy
por: Fanotto, Valentina, et al.
Publicado: (2018)

Third-line chemotherapy in advanced gastric cancer: A systematic review and meta-analysis
por: Zheng, Yu, et al.
Publicado: (2017)

Clinical significance of serum tumor markers for advanced gastric cancer with the first-line chemotherapy
por: Sun, Zhiwei, et al.
Publicado: (2019)

Concurrence of Gastric Cancer and Incidental Pulmonary Embolism May Be a Prognostic Factor for Advanced Gastric Cancer Patients with Incidental Pulmonary Embolism
por: Qiu, Meiqing, et al.
Publicado: (2021)

Outcomes of Third-Line Docetaxel-Based Chemotherapy in Advanced Gastric Cancer Who Failed Previous Oxaliplatin-Based and Irinotecan-Based Chemotherapies
por: Lee, Min Jeong, et al.
Publicado: (2012)

Combination Chemotherapy with 5-Fluorouracil and Heptaplatin as First-line Treatment in Patients with Advanced Gastric Cancer
por: Min, Young Joo, et al.
Publicado: (2004)

First-line chemotherapy with capecitabine/oxaliplatin for advanced gastric cancer: A phase I study
por: Satake, Hironaga, et al.
Publicado: (2017)

Correlation Between Hemoglobin Levels and the Prognosis of First-Line Chemotherapy in Patients with Advanced Gastric Cancer
por: Wei, Qing, et al.
Publicado: (2020)

Association of inflammatory markers with survival in patients with advanced gastric cancer treated with immune checkpoint inhibitors combined with chemotherapy as first line treatment
por: Wan, Mingyu, et al.
Publicado: (2022)

Abdominal Visceral-to-Subcutaneous Fat Volume Ratio Predicts Survival and Response to First-Line Palliative Chemotherapy in Patients with Advanced Gastric Cancer
por: Aringhieri, Giacomo, et al.
Publicado: (2023)

Prealbumin-to-Globulin Ratio Can Predict the Chemotherapy Outcomes and Prognosis of Patients with Gastric Cancer Receiving First-Line Chemotherapy
por: Wang, Zhuo, et al.
Publicado: (2020)

Perioperative chemotherapy more of a benefit for overall survival than adjuvant chemotherapy for operable gastric cancer: an updated Meta-analysis
por: Yang, Ya’nan, et al.
Publicado: (2015)

Mutational Profile Evaluates Response and Survival to First‐Line Chemotherapy in Lung Cancer
por: He, Yayi, et al.
Publicado: (2020)

Modified FOLFIRI as Second-Line Chemotherapy after Failure of Modified FOLFOX-4 in Advanced Gastric Cancer
por: Jeon, Eun Kyoung, et al.
Publicado: (2011)

Evaluation of Outcome and Tolerability of Combination Chemotherapy with Capecitabine and Oxaliplatin as First Line Therapy in Advanced Gastric Cancer
por: Mashhadi, Mohammad Ali, et al.
Publicado: (2016)

Efficacy of Acupuncture and Moxibustion as a Subsequent Treatment after Second-Line Chemotherapy in Advanced Gastric Cancer
por: Zhang, Yong-jie, et al.
Publicado: (2020)

Unresectable Advanced Gastric Cancer with Skin Invasion followed by Total Gastrectomy after Second-Line Chemotherapy
por: Maki, Hidenori, et al.
Publicado: (2019)

New prognostic model for patients with advanced gastric cancer: Fluoropyrimidine/platinum doublet for first-line chemotherapy
por: Koo, Dong-Hoe, et al.
Publicado: (2021)

Prognostic value of tumor mutation burden in patients with advanced gastric cancer receiving first-line chemotherapy
por: Duan, Xiao-Peng, et al.
Publicado: (2023)

Fingernails changes associated with chemotherapy in breast cancer: Muehrcke’s lines
por: Chang, Xiaosong, et al.
Publicado: (2018)

Safety and efficacy of tislelizumab plus chemotherapy for first‐line treatment of advanced esophageal squamous cell carcinoma and gastric/gastroesophageal junction adenocarcinoma
por: Qiu, Hai‐Bo
Publicado: (2020)

Decrease in Blood Neutrophil-to-Lymphocyte Ratio Indicates Better Survival After Neoadjuvant Chemotherapy in Patients With Advanced Gastric Cancer
por: Liu, Ziyi, et al.
Publicado: (2021)

Nab-paclitaxel - Third-line chemotherapy in advanced gallbladder cancer
por: Patel, Amol, et al.
Publicado: (2020)

Tislelizumab plus chemotherapy is more cost-effective than chemotherapy alone as first-line therapy for advanced non-squamous non-small cell lung cancer
por: Liang, Xueyan, et al.
Publicado: (2023)

First-line pembrolizumab/placebo plus trastuzumab and chemotherapy in HER2-positive advanced gastric cancer: KEYNOTE-811
por: Chung, Hyun Cheol, et al.
Publicado: (2020)

Economic Evaluation of First-Line Adjuvant Chemotherapies for Resectable Gastric Cancer Patients in China
por: Tan, Chongqing, et al.
Publicado: (2013)

Retrospective comparison of flot and modified dcf as first-line chemotherapy in metastatic gastric adenocarcinoma
por: GÜRLER, Fatih, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_q2bqgu9hmb9o8afui4pm2i2nf2